Holen Sie sich die Stockscreener-App
4.25
0.00%
0.00
Handel nachbörslich:
4.17
-0.08
-1.88%
Schlusskurs vom Vortag:
$4.25
Offen:
$4.25
24-Stunden-Volumen:
186.30K
Relative Volume:
1.17
Marktkapitalisierung:
$219.71M
Einnahmen:
$81.06M
Nettoeinkommen (Verlust:
$-55.55M
KGV:
-3.7281
EPS:
-1.14
Netto-Cashflow:
$-47.98M
1W Leistung:
+15.49%
1M Leistung:
+24.63%
6M Leistung:
+55.11%
1J Leistung:
-28.57%
1-Tages-Spanne:
$4.01
$4.34
1-Wochen-Bereich:
$3.49
$4.34
52-Wochen-Spanne:
$2.03
$7.05
Sight Sciences Inc Stock (SGHT) Company Profile
Firmenname
Sight Sciences Inc
Sektor
Branche
Telefon
(415) 889-0550
Adresse
4040 CAMPBELL AVE,, MENLO PARK
Vergleichen Sie SGHT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SGHT
Sight Sciences Inc
|
4.25 | 213.01M | 81.06M | -55.55M | -47.98M | -1.14 |
|
ABT
Abbott Laboratories
|
129.40 | 228.63B | 43.11B | 13.98B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
102.50 | 152.25B | 18.49B | 2.51B | 3.23B | 1.68 |
|
SYK
Stryker Corp
|
378.95 | 144.00B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.91 | 118.82B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
77.68 | 45.89B | 5.69B | 4.14B | 577.90M | 6.96 |
Sight Sciences Inc Stock (SGHT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-08 | Hochstufung | Lake Street | Hold → Buy |
| 2024-12-06 | Eingeleitet | UBS | Buy |
| 2024-11-04 | Herabstufung | Lake Street | Buy → Hold |
| 2024-08-21 | Eingeleitet | Lake Street | Buy |
| 2023-09-12 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-09-12 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-09-12 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-08-24 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-07-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-01-06 | Hochstufung | Stifel | Hold → Buy |
| 2022-10-04 | Eingeleitet | Needham | Hold |
| 2022-07-26 | Eingeleitet | Stifel | Hold |
| 2022-02-03 | Eingeleitet | William Blair | Outperform |
| 2022-01-07 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
Alle ansehen
Sight Sciences Inc Aktie (SGHT) Neueste Nachrichten
Sight Sciences, Inc. (NASDAQ:SGHT) Q2 2025 Earnings Call Transcript - MSN
Real time breakdown of Sight Sciences Inc. stock performance [Market Volume Summary]Daily Profit Maximizing Tips - Newser
Sight Sciences’ Earnings Call: Balancing Growth and Challenges - TipRanks
Will Sight Sciences Inc. see short term momentumSafe Investment Ideas with Growth Upside - Newser
Is Sight Sciences Inc. Stock a Good Fit for Conservative InvestorsEntry Optimization Guide with Volume Analysis - Newser
Analyzing Sight Sciences Inc. with risk reward ratio chartsFree Community Shared Smart Money Signals - Newser
Will Sight Sciences Inc. price bounce be sustainableFree AI Driven Buy Alert Trade Blueprint - Newser
Sight Sciences, Inc. (NASDAQ:SGHT) Just Reported And Analysts Have Been Lifting Their Price Targets - 富途牛牛
Sight Sciences (NASDAQ:SGHT) Upgraded at Lake Street Capital - Defense World
Sight Sciences (NASDAQ:SGHT) Raised to Hold at Wall Street Zen - Defense World
Will earnings trigger a reversal in Sight Sciences Inc.Free Conservative Long Term Growth Plans - Newser
Chart based exit strategy for Sight Sciences Inc.Free Price Action Based Buy Opportunity List - Newser
Risk adjusted return profile for Sight Sciences Inc. analyzedPrice Action Trading with Volume Confirmation - Newser
Sector Leaders Rotate Capital Into Sight Sciences Inc.Community Shared Smart Money Signals Show Movement - metal.it
Sight Sciences raises 2025 revenue guidance to $72M–$76M amid strong OMNI growth and strategic focus on MIGS leadership - MSN
Compared to Estimates, Sight Sciences (SGHT) Q2 Earnings: A Look at Key Metrics - MSN
Does Sight Sciences (NASDAQ:SGHT) Have A Healthy Balance Sheet? - simplywall.st
A Quick Look at Today's Ratings for Sight Sciences(SGHT.US), With a Forecast Between $4 to $5 - 富途牛牛
Sight Sciences, Inc. (SGHT) Reports Q2 Loss, Tops Revenue Estimates - NewsBreak: Local News & Alerts
Sight Sciences Reports Q2 EPS, Revenue Above Consensus, Glaucoma Ordering Accounts Reach New High - AInvest
Sight Sciences stock rating upgraded by Lake Street on stabilizing business - Investing.com Australia
Sight Sciences shares surge 17.75% intraday after strong Q2 earnings and upgraded rating by Lake Street analyst. - AInvest
Sight Sciences' Q2 2025: Navigating Contradictions in TearCare Reimbursement and Market Dynamics - AInvest
Sight Sciences Boosts 2025 Revenue Guidance to $72M-$76M on OMNI Growth and MIGS Leadership Focus - AInvest
Earnings call transcript: Sight Sciences Q2 2025 beats revenue expectations By Investing.com - Investing.com Nigeria
Earnings call transcript: Sight Sciences Q2 2025 beats revenue expectations - Investing.com
Sight Sciences August 2025 slides: Targeting growth in $9B eye care market despite Q1 headwinds - Investing.com Australia
Sight Sciences 2025 Q2 Earnings Slight Improvement in Losses Amid Revenue Decline - AInvest
Sight Sciences Reports Q2 2025 Financial Results - TipRanks
Sight Sciences Lifts Outlook Despite Revenue Slump - Finimize
Sight Sciences Releases Second Quarter Results and Raises Full-Year Guidance - VisionMonday.com
Sight Sciences Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Transcript : Sight Sciences, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Sight Sciences reports Q2 EPS (23c), consensus (28c) - TipRanks
Sight Sciences: Navigating Revenue Headwinds and Regulatory Challenges to Secure Long-Term Growth - AInvest
Sight Sciences: A Resilient Earnings Beat Signals Undervaluation and Growth in Ophthalmic Innovation - AInvest
Sight Sciences Raises Full-Year Revenue Guidance - TipRanks
Sight Sciences earnings beat by $0.03, revenue topped estimates - Investing.com Canada
Sight Sciences Reports Second Quarter 2025 Financial Results and Raises Full Year 2025 Revenue Guidance - GlobeNewswire
SAHARA trial demonstrates sustained TearCare benefits for evaporative DED - Ophthalmology Times
Sight Sciences releases cost-utility analysis comparing TearCare and cyclosporine 0.05% in dry eye - Optometry Times
Strategies to average down on Sight Sciences Inc.Day Trading Setup Forecast with Trend Model - Newser
Sight Sciences (SGHT) to Release Quarterly Earnings on Thursday - Defense World
What high frequency data says about Sight Sciences Inc.Equity Signal Recap With Long-Term Summary - Newser
What makes Sight Sciences Inc. stock price move sharplyFree Fundamental Growth Stock Analysis - Newser
Will Sight Sciences Inc. outperform the marketFree Community Verified Stock Suggestions - Newser
Finanzdaten der Sight Sciences Inc-Aktie (SGHT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.31%
1.36%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):